Literature DB >> 14693990

Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.

Richard J Stevens1, Ruth L Coleman, Amanda I Adler, Irene M Stratton, David R Matthews, Rury R Holman.   

Abstract

OBJECTIVE: Patients with diabetes have a higher case fatality rate in myocardial infarction (MI) or stroke than those without diabetes: that is, MI and stroke are more often fatal if diabetes is present. We investigated whether the risk of MI or stroke being fatal in type 2 diabetes can be estimated using information available around the time diabetes is diagnosed. RESEARCH DESIGN AND METHODS: Analyses were based on 674 cases of MI (351 fatal) that occurred in 597 of 5,102 U.K. Prospective Diabetes Study (UKPDS) patients for whom covariate data were available during a median follow-up of 7 years. Multivariate logistic regression was used to examine differences in risk factors, measured within 2 years of diagnosis of diabetes, between fatal and nonfatal MI. Similar analyses were performed for 234 strokes (48 fatal) that occurred in 199 patients.
RESULTS: Patients with fatal MI had higher HbA(1c) than those with nonfatal MI (odds ratio 1.17 per 1% HbA(1c), P = 0.014). Patients with fatal stroke had higher HbA(1c) than those with nonfatal stroke (odds ratio 1.37 per 1% HbA(1c), P = 0.007). Other risk factors for MI case fatality included increased age, blood pressure, and urine albumin level.
CONCLUSIONS: The risk of MI or stroke being fatal in type 2 diabetes is associated with risk factors, including HbA(1c), measured many years before onset of MI or stroke. Equations have been added to the UKPDS Risk Engine to estimate likely case fatality rates in MI and stroke.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693990     DOI: 10.2337/diacare.27.1.201

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  67 in total

1.  Insulin suppresses ischemic preconditioning-mediated cardioprotection through Akt-dependent mechanisms.

Authors:  Tanner M Fullmer; Shaobo Pei; Yi Zhu; Crystal Sloan; Robert Manzanares; Brandon Henrie; Karla M Pires; James E Cox; E Dale Abel; Sihem Boudina
Journal:  J Mol Cell Cardiol       Date:  2013-08-30       Impact factor: 5.000

Review 2.  Central nervous system involvement in diabetes mellitus.

Authors:  Dinesh Selvarajah; Solomon Tesfaye
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

Review 3.  Statins and the prevention of stroke in diabetes.

Authors:  Mary Ann Banerji
Journal:  Curr Diab Rep       Date:  2005-02       Impact factor: 4.810

4.  The operative risk factors in the metabolic syndrome: is it lipids and high BP or are there direct vascular effects of insulin resistance and obesity.

Authors:  Fabrice M A C Martens; Frank L J Visseren
Journal:  Curr Diab Rep       Date:  2007-02       Impact factor: 4.810

5.  The quality of diabetes care following hospitalization for ischemic stroke.

Authors:  Nancy Pandhi; Maureen A Smith; Amy J H Kind; Jennifer R Frytak; Michael D Finch
Journal:  Cerebrovasc Dis       Date:  2009-01-29       Impact factor: 2.762

6.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

7.  Development of appropriate coronary heart disease risk prediction models in HIV-infected patients.

Authors:  Morris Schambelan; Peter W F Wilson; Kevin E Yarasheski; W Todd Cade; Victor G Dávila-Román; Ralph B D'Agostino; Tarek A Helmy; Matthew Law; Kristin E Mondy; Sharon Nachman; Linda R Peterson; Signe W Worm
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

8.  Assessing the Effect of Clinical Inertia on Diabetes Outcomes: a Modeling Approach.

Authors:  Maria F Correa; Yan Li; Hye-Chung Kum; Mark A Lawley
Journal:  J Gen Intern Med       Date:  2018-12-18       Impact factor: 5.128

9.  Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders.

Authors:  David J Heal; Jane Gosden; Sharon L Smith
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

10.  Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians.

Authors:  Michel P Hermans; Jean-Charles Fruchart
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.